IPO - Immunome Inc.

Form Type: 8-K

Filing Date: 2025-01-30

Corporate Action: Ipo

Type: New

Accession Number: 000110465925007610

Filing Summary: On January 29, 2025, Immunome, Inc. entered into an underwriting agreement with J.P. Morgan Securities LLC, TD Securities (USA) LLC, Leerink Partners LLC, and Guggenheim Securities, LLC for a public offering of 19,354,839 shares of its common stock at a price of $7.75 per share, expected to raise approximately $150 million before expenses. The offering is expected to close on January 31, 2025, contingent upon customary conditions. Additionally, the underwriters received a 30-day option to purchase up to 2,903,225 additional shares at the same price. The offering is conducted under a shelf registration statement that became effective upon filing. A press release announcing the commencement and pricing of the offering was issued on the same day.

Document Link: View Document

Form Type: 424B5

Filing Date: 2025-01-29

Corporate Action: Ipo

Type: New

Accession Number: 000110465925007230

Filing Summary: Immunome Inc. is conducting an offering of $125,000,000 worth of shares of common stock, trading under the symbol 'IMNM' on the Nasdaq Capital Market. The pricing for these shares will be determined through negotiations between the company and the lead underwriters. The last reported sale price before the offer was $9.24 per share. The company has indicated that its CEO, Clay Siegall, is interested in purchasing up to $1.0 million worth of shares. The underwriters also have the option to purchase an additional $18,750,000 of shares within 30 days of this supplement. Immunome focuses on developing targeted oncology therapies with multiple assets in various stages of development including IND-cleared and clinical assets. The offering is subject to risks, and investors should read the risk factors detailed in the document before participating. The company maintains a significant amount of cash and marketable securities, estimated at approximately $217.3 million as of December 31, 2024, which supports its operational and development strategies. The net proceeds from this offering are intended for ongoing clinical development of its pipeline assets and other corporate purposes. The volatile nature of the biotechnology sector is acknowledged as a risk for investment.

Document Link: View Document

Form Type: 8-K

Filing Date: 2025-01-29

Corporate Action: Ipo

Type: New

Accession Number: 000110465925007198

Filing Summary: On January 29, 2025, Immunome Inc. announced the commencement of an underwritten public offering of its common stock, which is also referred to as the Offering. The offering will be detailed in a preliminary prospectus supplement to an automatic shelf registration statement on Form S-3, which was filed with the SEC on February 13, 2024. The company expects to report approximately $217.3 million in cash, cash equivalents, and marketable securities as of December 31, 2024. Specific financial statements for the quarter and year ended December 31, 2024, will be made available only after the offering is completed. The document further outlines Immunome's ongoing commitment towards developing targeted oncology therapies, detailing a diverse pipeline that includes both clinical and preclinical assets, such as varegacestat, IM-1021, IM-3050, and others. The report emphasizes their goal of transforming cancer treatment by focusing on novel therapeutic targets and robust preclinical foundations to guide their development path. Forward-looking statements regarding corporate strategies, timelines for regulatory submissions and clinical trials, and potential financial performance are also included, highlighting the inherent uncertainties related to these projections. Lastly, the filing identifies the registrant as an emerging growth company, denoting a status that may influence their reporting and operational strategies.

Document Link: View Document